세계의 후천성면역결핍증후군(AIDS) 시장 보고서(2025년)

Acquired Immunodeficiency Syndrome (AIDS) Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

후천성면역결핍증후군(AIDS) 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 시장 성장은 장시간 작용 주사요법에 대한 수요 증가, 노출 전 예방제(PrEP) 채용 확대, HIV 치료 연구 투자 증가, HIV 케어를 위한 원격 의료 서비스 확대, 맞춤형 의료에 대한 주목 증가, HIV의 조기 진단에 대한 의식 증가 등에 기인한다고 생각됩니다. 좋은 성장, HIV 관리에서 디지털 건강 솔루션에 대한 수요 증가, 기능적 HIV 치료 전략에 대한 관심 증가, 의약품에서 인공지능의 역할 확대 등이 있습니다.

HIV 감염률 증가는 후천성면역결핍증후군(AIDS) 시장의 성장을 가속할 것으로 예측됩니다. HIV 감염은 인간 면역 결핍 바이러스에 의해 야기되는 증상을 말하며, 면역계를 약화시킴으로써 감염과 질병과 싸우기가 어렵습니다. HIV 감염률 증가는 감염자와의 무방비 성 협상, 주사 바늘 공유, 오염된 혈액 제제의 섭취, 여러 성적 파트너의 존재, 면역력 저하 및 기존 성 감염과 같은 요인에 기인합니다. 에이즈 관리는 조기 진단 촉진, 효과적인 항레트로바이러스 치료 접근성 개선, 예방 전략 강화, 바이러스 확산을 보다 잘 제어하기 위한 건강 관리 시스템 강화로 HIV 환자를 지원합니다. 예를 들어, 2024년 11월에 유럽 질병 예방 관리 센터(ECDC)가 보고한 2023년 신규 HIV 감염자 수는 역내 53개국 중 47개국에서 11만 2,883명이었으며, 이 중 2만 4,731명이 유럽 연합/유럽 경제 영역(EU/EEA)에서 발생했습니다. 이는 HIV 진단의 조율이 전년 대비 2.4% 증가한 것을 의미하며 HIV 감염의 유병률이 높아지고 있음을 나타내며 후천성면역결핍증후군(AIDS) 시장의 확대에 기여하고 있습니다.

후천성면역결핍증후군(AIDS) 시장에서 사업을 전개하는 기업은 환자의 복약 준수를 향상시키고, 투여 횟수를 줄이고, 매일 경구 항레트로바이러스 치료를 대체하는 보다 편리한 치료법을 제공하기 위해 장시간 작용형 주사제와 같은 혁신적인 치료법 개방 발에 주력하고 있습니다. 이 주사제는 유효 성분이 시간이 지남에 따라 천천히 방출되도록 설계되어 있기 때문에 기존의 경구 약물에 비해 투여 횟수를 줄일 수 있습니다. 예를 들어, 2025년 1월 영국에 본사를 둔 제약 회사인 GSK plc.는 유럽위원회로부터 보카브리아(카보테그라비르)와 레캄비스(릴피비린)로 구성된 지속형 주사제 치료제에 대한 승인을 받았습니다. 일반적으로 승인된 치료 계획에 따라 1-2개월마다 근육 내 주사로 투여됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 후천성면역결핍증후군(AIDS) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 성장률 분석
• 세계의 후천성면역결핍증후군(AIDS) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 후천성면역결핍증후군(AIDS) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 후천성면역결핍증후군(AIDS) 전체 시장(TAM)

제6장 시장 세분화

• 세계의 후천성면역결핍증후군(AIDS) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 인간 면역결핍 바이러스 1
• 인간 면역결핍 바이러스 2
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 뉴클레오사이드-아날로그 역전사효소 억제제
• 비뉴클레오사이드 역전사효소 억제제
• 융합 억제제
• CCR5 길항제 및 부착 후 억제제
• 프로테아제 억제제
• 인테그라제 억제제
• 노출 전 예방 및 노출 후 예방요법
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 비경구
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 기타 용도
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 오프라인
• 온라인
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 인간 면역결핍 바이러스 1(HIV-1) 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 항레트로바이러스 치료(ART)
• 노출 전 예방(PrEP)
• 노출 후 예방(PEP)
• HIV-1 진단 검사
• HIV-1 백신 개발
• HIV-1 기회감염 관리
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 인간 면역결핍 바이러스 2(HIV-2) 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• HIV-2 항레트로바이러스 치료(ART)
• HIV-2 진단 검사
• HIV-2 감시 및 역학
• HIV-2 백신 연구
• HIV-2 동시 감염 관리

제7장 지역별/국가별 분석

• 세계의 후천성면역결핍증후군(AIDS) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 후천성면역결핍증후군(AIDS) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 후천성면역결핍증후군(AIDS) 시장 : 경쟁 구도
• 후천성면역결핍증후군(AIDS) 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson and Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bristol-Myers Squibb Company
• Abbott
• GSK plc
• Takeda Pharmaceuticals
• Gilead Sciences
• Viatris Inc.
• Teva Pharmaceuticals
• Aurobindo Pharma
• Cipla Ltd
• Shionogi and Co.
• Dr. Reddy's Laboratories
• Lupin
• Hetero Drugs Limited
• Glenmark Pharmaceuticals Limited
• ViiV Healthcare

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 후천성면역결핍증후군(AIDS) 시장(2029년) : 새로운 기회를 제공하는 국가
• 후천성면역결핍증후군(AIDS) 시장(2029년) : 새로운 기회를 제공하는 부문
• 후천성면역결핍증후군(AIDS) 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by attacking and destroying CD4 T cells. This leaves the body susceptible to opportunistic infections, severe illnesses, and certain cancers unless effective antiretroviral treatment (ART) is administered. AIDS management involves a combination of ART, regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to enhance patient outcomes and quality of life.

The main types of acquired immunodeficiency syndrome (AIDS) include human immunodeficiency virus 1 (HIV-1) and human immunodeficiency virus 2 (HIV-2). HIV-1 is a retrovirus that primarily infects CD4+ T cells, leading to progressive immunodeficiency and, if untreated, the development of AIDS. Drugs used in treating AIDS include nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, protease inhibitors, integrase inhibitors, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). These drugs are administered orally or parenterally and are used in various settings, including hospital pharmacies, retail pharmacies, and others, with distribution via both offline and online channels.

The acquired immunodeficiency syndrome (AIDS) market research report is one of a series of new reports from The Business Research Company that provides acquired immunodeficiency syndrome (AIDS) market statistics, including acquired immunodeficiency syndrome (AIDS) industry global market size, regional shares, competitors with a acquired immunodeficiency syndrome (AIDS) market share, detailed acquired immunodeficiency syndrome (AIDS) market segments, market trends and opportunities, and any further data you may need to thrive in the acquired immunodeficiency syndrome (AIDS) industry. This acquired immunodeficiency syndrome (AIDS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acquired immunodeficiency syndrome (AIDS) market size has grown strongly in recent years. It will grow from $32.09 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to the rising rates of HIV infections, increased government funding for HIV treatment, the expansion of global awareness programs, improvements in diagnostic capabilities, and growing support from non-governmental organizations.

The acquired immunodeficiency syndrome (AIDS) market size is expected to see strong growth in the next few years. It will grow to $41.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period can be attributed to the rising demand for long-acting injectable therapies, increasing adoption of pre-exposure prophylaxis (PrEP), growing investment in HIV cure research, the expansion of telemedicine services for HIV care, a heightened focus on personalized medicine, and increased awareness about early HIV diagnosis. Key trends during this period include a shift toward single-tablet regimens, a growing preference for injectable and implantable HIV treatments, a rising demand for digital health solutions in HIV management, increased interest in functional HIV cure strategies, and the expanding role of artificial intelligence in drug discovery.

The increasing rates of HIV infections are expected to drive the growth of the acquired immunodeficiency syndrome (AIDS) market. HIV infections refer to the condition caused by the human immunodeficiency virus, which weakens the immune system, making it harder for the body to fight infections and diseases. The rising rates of HIV infections can be attributed to factors such as unprotected sexual intercourse with an infected individual, sharing needles, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or existing sexually transmitted infections. Management of AIDS helps patients with HIV by promoting early diagnosis, improving access to effective antiretroviral therapies, enhancing prevention strategies, and strengthening healthcare systems to better control the spread of the virus. For example, in November 2024, the European Centre for Disease Prevention and Control (ECDC) reported 112,883 new HIV diagnoses in 2023 across 47 out of 53 countries in the region, with 24,731 of these cases occurring in the European Union/European Economic Area (EU/EEA). This marks a 2.4% increase in the crude rate of HIV diagnoses compared to the previous year, indicating the growing prevalence of HIV infections and contributing to the expansion of the AIDS market.

Companies operating in the AIDS market are focusing on the development of innovative therapies such as long-acting injectables to improve patient adherence, reduce dosing frequency, and offer a more convenient alternative to daily oral antiretroviral treatments. These injectables are designed to release their active ingredients slowly over time, which allows for less frequent dosing compared to traditional oral medications. For example, in January 2025, GSK plc., a UK-based pharmaceutical company, received approval from the European Commission for a long-acting injectable treatment consisting of Vocabria (cabotegravir) and Rekambys (rilpivirine). This treatment, approved for adolescents aged 12 years and older living with HIV, is administered through an intramuscular injection, typically every one or two months, depending on the treatment plan. This long-acting formulation can improve adherence rates among adolescents who may struggle with daily pill regimens.

In November 2024, Gilead Sciences Inc., a U.S.-based biopharmaceutical company, acquired investigational assets for the HTI therapeutic HIV vaccine from AELIX Therapeutics. Through this acquisition, Gilead aims to enhance its HIV treatment portfolio by advancing research into functional HIV cures and potentially reducing the reliance on lifelong antiretroviral therapy. AELIX Therapeutics, based in Spain, focuses on developing treatments and vaccines for AIDS.

Major players in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare.

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acquired immunodeficiency syndrome (AIDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acquired immunodeficiency syndrome (AIDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired immunodeficiency syndrome (AIDS) market consists of sales of products such as long-acting injectable antiretrovirals, broadly neutralizing antibodies (bNAbs), therapeutic HIV vaccines, latency-reversing agents, capsid inhibitors, attachment inhibitors, maturation inhibitors, and pharmacokinetic enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Immunodeficiency Syndrome (AIDS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired immunodeficiency syndrome (aids) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acquired immunodeficiency syndrome (aids) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired immunodeficiency syndrome (aids) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2
• 2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications
• 5) By Distribution Channel: Offline; Online
• Subsegments:
• 1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management
• 2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acquired Immunodeficiency Syndrome (AIDS) Market Characteristics

3. Acquired Immunodeficiency Syndrome (AIDS) Market Trends And Strategies

4. Acquired Immunodeficiency Syndrome (AIDS) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acquired Immunodeficiency Syndrome (AIDS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acquired Immunodeficiency Syndrome (AIDS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acquired Immunodeficiency Syndrome (AIDS) Market Growth Rate Analysis
• 5.4. Global Acquired Immunodeficiency Syndrome (AIDS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acquired Immunodeficiency Syndrome (AIDS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acquired Immunodeficiency Syndrome (AIDS) Total Addressable Market (TAM)

6. Acquired Immunodeficiency Syndrome (AIDS) Market Segmentation

• 6.1. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Immunodeficiency Virus 1
• Human Immunodeficiency Virus 2
• 6.2. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside-Analog Reverse Transcriptase Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Fusion Inhibitors
• CCR5 Anatagonists and Post-Attachment Inhibitors
• Protease Inhibitors
• Integrase Inhibitors
• Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
• 6.3. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Applications
• 6.5. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Offline
• Online
• 6.6. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Sub-Segmentation Of Human Immunodeficiency Virus 1 (HIV-1), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiretroviral Therapy (ART)
• Pre-Exposure Prophylaxis (PrEP)
• Post-Exposure Prophylaxis (PEP)
• HIV-1 Diagnostic Tests
• HIV-1 Vaccine Development
• HIV-1 Opportunistic Infection Management
• 6.7. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Sub-Segmentation Of Human Immunodeficiency Virus 2 (HIV-2), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiretroviral Therapy (ART) For HIV-2
• HIV-2 Diagnostic Tests
• HIV-2 Surveillance And Epidemiology
• HIV-2 Vaccine Research
• Management Of HIV-2 Co-Infections

7. Acquired Immunodeficiency Syndrome (AIDS) Market Regional And Country Analysis

• 7.1. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market

• 8.1. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acquired Immunodeficiency Syndrome (AIDS) Market

• 9.1. China Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 9.2. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acquired Immunodeficiency Syndrome (AIDS) Market

• 10.1. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acquired Immunodeficiency Syndrome (AIDS) Market

• 11.1. Japan Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 11.2. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acquired Immunodeficiency Syndrome (AIDS) Market

• 12.1. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market

• 13.1. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market

• 14.1. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 14.2. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market

• 15.1. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 15.2. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acquired Immunodeficiency Syndrome (AIDS) Market

• 16.1. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acquired Immunodeficiency Syndrome (AIDS) Market

• 17.1. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acquired Immunodeficiency Syndrome (AIDS) Market

• 18.1. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acquired Immunodeficiency Syndrome (AIDS) Market

• 19.1. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acquired Immunodeficiency Syndrome (AIDS) Market

• 20.1. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market

• 21.1. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 21.2. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acquired Immunodeficiency Syndrome (AIDS) Market

• 22.1. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acquired Immunodeficiency Syndrome (AIDS) Market

• 23.1. North America Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 23.2. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acquired Immunodeficiency Syndrome (AIDS) Market

• 24.1. USA Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 24.2. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acquired Immunodeficiency Syndrome (AIDS) Market

• 25.1. Canada Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 25.2. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acquired Immunodeficiency Syndrome (AIDS) Market

• 26.1. South America Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 26.2. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market

• 27.1. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market

• 28.1. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 28.2. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acquired Immunodeficiency Syndrome (AIDS) Market

• 29.1. Africa Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 29.2. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Landscape And Company Profiles

• 30.1. Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Landscape
• 30.2. Acquired Immunodeficiency Syndrome (AIDS) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Acquired Immunodeficiency Syndrome (AIDS) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Abbott
• 31.3. GSK plc
• 31.4. Takeda Pharmaceuticals
• 31.5. Gilead Sciences
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceuticals
• 31.8. Aurobindo Pharma
• 31.9. Cipla Ltd
• 31.10. Shionogi and Co.
• 31.11. Dr. Reddy's Laboratories
• 31.12. Lupin
• 31.13. Hetero Drugs Limited
• 31.14. Glenmark Pharmaceuticals Limited
• 31.15. ViiV Healthcare

32. Global Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acquired Immunodeficiency Syndrome (AIDS) Market

34. Recent Developments In The Acquired Immunodeficiency Syndrome (AIDS) Market

35. Acquired Immunodeficiency Syndrome (AIDS) Market High Potential Countries, Segments and Strategies

• 35.1 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료